Micropharma Ltd., a pioneer in the development of innovative and effective probiotics, announced today its plans to launch a portfolio of natural supplements and food ingredient solutions aimed at addressing specific health markers to help maintain and improve health and wellness. Adding to its strong pipeline with eight patents filed since 2003, the first probiotic to be launched later this year has been clinically shown to maintain healthy cholesterol levels. Many adults need help in maintaining healthy cholesterol levels because their cholesterol levels exceed those recommended by doctors.
To date, Micropharma and its partners have invested more than $3.5 million into research creating ProSelect™, a proprietary technology that isolates non-GMO, live probiotic candidates with the potential to promote better health and help the body support healthy cardiovascular and digestive systems.
“Through innovative research and development, Micropharma is using state-of-the-art scientific approaches to yield powerful natural products,” states Ryan Jones, CEO of Micropharma Ltd. “We have two medical doctors on our team, and were the first company to do production optimization for actives within the probiotics field. Our technology and product lines are backed by rigorous peer-reviewed science and extensive consumer and market research, setting us apart from the competition.”
Probiotics are becoming increasingly popular among today’s health conscious consumers looking to enhance their well-being. Sales from foods and supplements boasting probiotic effects are estimated at $28 billion for 2011 and forecast to be approximately $42 billion by 20161; Danone Research has invested $8 million in Micropharma. The company is poised to accelerate this growth, transforming the category by clinically proving probiotics’ effects beyond digestive health.